Key result
Clopidogrel-aspirin 24-72 hours post-stroke reduces new strokes ~20% vs aspirin, concentrated in ABCD-GENE scores 0-5.
Why the study?
Does clopidogrel-aspirin therapy reduce new stroke compared to aspirin alone in patients with minor ischemic stroke or TIA when stratified by ABCD-GENE score?
Does clopidogrel-aspirin therapy reduce new stroke compared to aspirin alone in patients with minor ischemic stroke or TIA when stratified by ABCD-GENE score?
Answers are grounded in this paper and cite their sources.
May support ABCD-GENE-guided dual therapy in minor stroke; hypothesis-generating pending dedicated RCTs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted a letter in Minor ischemic stroke or transient ischemic attack (TIA) (n=4,693). Clopidogrel-aspirin vs. Aspirin alone was evaluated on New stroke (ischemic and hemorrhagic) (HR 0.80, 95% CI 0.65-0.99, p=0.04). Clopidogrel-aspirin therapy initiated 24-72 hours after minor stroke or TIA reduced the risk of new stroke compared to aspirin alone, with the benefit concentrated in patients with an ABCD-GENE score of 0-5.
Synapse has enriched 10 related papers. Consider them for comparative context: